Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors

Several groups have proposed that genotypic determinants in gag and the gp41 cytoplasmic domain (gp41-CD) reduce protease inhibitor (PI) susceptibility without PI-resistance mutations in protease. However, no gag and gp41-CD mutations definitively responsible for reduced PI susceptibility have been...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: Manasa, Justen, Varghese, Vici, Pond, Sergei L. Kosakovsky, Rhee, Soo-Yon, Tzou, Philip L., Fessel, W. Jeffrey, Jang, Karen S., White, Elizabeth, Rögnvaldsson, Thorsteinn, Katzenstein, David A., Shafer, Robert W.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5599673/
https://ncbi.nlm.nih.gov/pubmed/28912582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-11893-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars